Aquestive receives two new US patents for Anaphylm, extending protection to 2037

Aquestive Therapeutics, Inc.

USPTO issued U.S. patent nos. 12,427,121 and 12,443,850 covering epinephrine prodrug compositions for sublingual film delivery.
Patents expire May 4, 2037, subject to extensions; protect proprietary composition enabling oral film delivery.
Anaphylm (dibutepinephrine) sublingual film, if FDA approved, would be first oral rescue treatment for severe allergic reactions.
PDUFA target action date for Anaphylm is January 31, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.